The global trigeminal neuralgia treatment market is expected to reach a value of USD 799 Million by 2027, with a CAGR of 3.9% during the forecast period, 2020–2027. Trigeminal neuralgia (TN) is a rare disorder that causes severe chronic pain due to damage to the trigeminal nerve, which transfers sensation from the face to the brain. It is primarily caused by blood vessels pressing towards the root of the trigeminal nerve, which helps the nerve transmit signs of discomfort that are felt as stabbing pains. Symptoms vary from moderate to extreme facial discomfort, which is often caused by teeth grinding, talking, or brushing.
Rising Popularity of Anticonvulsant Medications in the Treatment of Trigeminal Neuralgia
Anticonvulsant medications are formulated specifically for the treatment of epilepsy. As per WHO statistics, epilepsy affects about 50 million people globally. The increasing incidence of TN will increase the adoption of anticonvulsants. As per the American Association of Neurological Surgeons, an estimated 150,000 people are diagnosed with TN every year. Anticonvulsants are gaining popularity as they are effective in treating TN. Carbamazepine drugs, such as Tegretol and Carbatrol, are commonly used anticonvulsants. Other anticonvulsant drugs that may be used include oxcarbazepine (Trileptal), lamotrigine (Lamictal), and phenytoin (Dilantin, Phenytek). However, patients face a substantial burden of illness and multiple side effects by prolonged usage of drugs, such as amnesia, nausea, drowsiness, dizziness, and unstableness.
Got questions about your regional growth of
Trigeminal Neuralgia Treatment Market?
Just drop us a line or call on +1 646 480 7505
Extensive Drug Pipeline for Trigeminal Neuralgia Treatment Comprising Chemicals and Biologics
The drug pipeline of TN is extensive and composed of a mixture of chemicals and biologics. However, in phase III of clinical trials, the number of chemical-based drug molecules is more in contrast with biological drugs. Improved innovative drugs are a welcome addition to meet the unmet needs of trigeminal neuralgia patients and will create a lucrative opportunity for the market in the coming years.
Trigeminal Neuralgia Treatment Market: Highlights
Trigeminal Neuralgia Treatment Market: Segmentation
By Type
By End User
By Region
North America
Europe
Asia-Pacific
South America
The Middle East and Africa
" Crucial Insights The Report Provides:"
* Known and Unknown Adjacencies Influencing the Growth of Market
* Explorable Revenue Sources
* Customer Behaviour Analysis
* Target Partners
* Customized Geographical Data Based on Customers as well as Competitors
* Analysis of Market Size and CAGR between the Forecast Periods